Hence, two decades after the seminal observations linking familial PAH with TGF-β superfamily signaling, there are signs that targeting this pathway—now thought to control multiple PAH disease processes—could offer hope for transformative PAH treatments. This evidence concerns the gene TGFB1 and pulmonary arterial hypertension.